Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
JBPOS0551
- Development stage
- Preclinical
- Lead developer
- Bio-Pharm Solutions
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
JBPOS0551 is a preclinical-stage small molecule candidate developed by Bio-Pharm Solutions for the treatment of neurological disorders, including epilepsy, infantile spasms (IS), Lennox-Gastaut syndrome (LGS), and chronic pain. Developed using the company's proprietary carbamate-based medicinal chemistry platform, JBPOS0551 is a follow-on compound to their lead asset JBPOS0101. The drug has been evaluated through the NIH NINDS Anticonvulsant Screening Program (ASP) and is currently designated as IND-ready, indicating it has completed the necessary preclinical safety and efficacy studies to begin human clinical trials.
- Other names
- JBPOS-0551JBPOS0551JBPOS 0551
Beyond the preview
Go deeper on JBPOS0551.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on JBPOS0551.